strontium ranelate 2g granules for oral suspension sachets sugar free
a a h pharmaceuticals ltd - strontium ranelate - granules for oral suspension - 2gram
strontium bromatum pellet
hahnemann laboratories, inc. - strontium bromide (unii: 1ng558x5vj) (strontium cation - unii:37077s2c93) -
strontium carbonicum pellet
hahnemann laboratories, inc. - strontium carbonate (unii: 41ypu4mmca) (strontium cation - unii:37077s2c93) -
strontium fluoratum pellet
hahnemann laboratories, inc. - strontium fluoride (unii: efy8gjs81z) (strontium fluoride - unii:efy8gjs81z) -
strontium iodatum pellet
hahnemann laboratories, inc. - strontium iodide (unii: f6v5hor0o5) (strontium iodide - unii:f6v5hor0o5) -
strontium metallicum pellet
hahnemann laboratories, inc. - strontium (unii: yzs2rpe8le) (strontium - unii:yzs2rpe8le) -
strontium phosphoricum pellet
hahnemann laboratories, inc. - strontium phosphate (unii: b7cf3bd0tt) (strontium cation - unii:37077s2c93) -
strontium metallicum pellet
hahnemann laboratories, inc. - strontium (unii: yzs2rpe8le) (strontium - unii:yzs2rpe8le) -
protos
servier laboratories nz ltd - strontium ranelate 2632mg - granules for oral suspension - 2 g - active: strontium ranelate 2632mg excipient: aspartame maltodextrin mannitol - treatment of severe (established) osteoporosis in postmenopausal women at high risk of fracture to reduce the risk of fracture.
esomeprazole strontium capsule, delayed release
sterling-knight pharmaceuticals, llc - esomeprazole strontium (unii: c5n25h3803) (esomeprazole - unii:n3pa6559ft) - healing of erosive esophagitis esomeprazole strontium is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. for those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole strontium may be considered. maintenance of healing of erosive esophagitis esomeprazole strontium is indicated to maintain symptom resolution and healing of erosive esophagitis. controlled studies do not extend beyond 6 months. symptomatic gastroesophageal reflux disease esomeprazole strontium is indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with gerd in adults. esomeprazole strontium is indicated for the reduction in the occurrence of gastric ulcers associated with continuous nsaid therapy in patients at risk for developing gastric ulcers. patients are considered to be at risk either due to their age (≥60) and/or documented history of gastric ul